help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zerwekh, J. E.
Right arrow Articles by Pak, C. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zerwekh, J. E.
Right arrow Articles by Pak, C. Y.

Journal of Clinical Endocrinology & Metabolism, Vol 49, 171-175, Copyright © 1979 by Endocrine Society

ARTICLES

An unique form of osteomalacia associated with end organ refractoriness to 1,25-dihydroxyvitamin D and apparent defective synthesis of 25- hydroxyvitamin D

JE Zerwekh, K Glass, J Jowsey and CY Pak

A 28-yr-old woman presented with hypocalcemia, hypophosphatemia, secondary hyperparthyroidism, and biopsy-proven osteomalacia despite treatment with vitamin D2, (17.5 mg/day). Three weeks after vitamin D2 treatment was stopped, she was found to have a low normal serum 25- hydroxyvitamin D (25OHD) and high serum 1 alpha, 25-dihydroxyvitamin D [1,25(OH)2D] of 18.6 ng/ml and 21.2 ng/dl, respectively. The fractional intestinal calcium absorption was low at 0.26. Treatment with 25OHD3 (20--50 micrograms/day) corrected the hypocalcemia and secondary hyperparathyroidism, raised intestinal calcium absorption, and reversed the skeletal lesions of osteomalacia. Serum 25OHD concentration rose to 51 ng/ml, while 1,25(OH)2D remained elevated. This case illustrates the probable operation of dual abnormalities in vitamin D metabolism. An impaired end organ responsiveness to 1,25(OH)2D was suggested by a low intestinal calcium absorption in the face of high serum 1,25(OH)2D. Moreover, there may have been a defective vitamin D-25-hydroxylase, since there was a relative refractoriness to treatment with large doses of vitamin D2, an inappropriately low serum 250HD after vitamin D2 therapy, and a responsiveness to treatment with 25OHD3.


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
J. B. Cheng, M. A. Levine, N. H. Bell, D. J. Mangelsdorf, and D. W. Russell
Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase
PNAS, May 18, 2004; 101(20): 7711 - 7715.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
P. J. Malloy, J. W. Pike, and D. Feldman
The Vitamin D Receptor and the Syndrome of Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets
Endocr. Rev., April 1, 1999; 20(2): 156 - 188.
[Abstract] [Full Text]

Home page
 ScienceHome page
M. Hughes, P. Malloy, D. Kieback, R. Kesterson, J. Pike, D Feldman, and B. O'Malley
Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets
Science, December 23, 1988; 242(4886): 1702 - 1705.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1979 by The Endocrine Society